Loading organizations...
Farmabase develops and manufactures veterinary medicines, focusing on health and welfare solutions for poultry and swine. The company offers a broad portfolio of products including therapeutics, anticoccidials, and antiparasitics, administered via feed, drinking water, and injectables. Its technical approach emphasizes rigorous scientific research, advanced product development within state-of-the-art laboratories, and compliance with global regulatory standards to ensure high-quality animal protein production.
The company was founded in 1994 in Brazil, driven by an insight into the need for effective and affordable solutions to manage and treat diseases in livestock. From its inception, Farmabase committed to pioneering innovation in animal health, establishing itself as an early adopter of Good Manufacturing Practices (GMP) and implementing total traceability processes for its products. This foundational commitment to quality and scientific rigor has guided its trajectory.
Farmabase serves a global client base of poultry and swine producers, operating in over 50 countries and approved by major animal protein exporters. The company's vision centers on continuously advancing animal care to promote the well-being of livestock, thereby contributing to the availability of higher quality animal protein for consumers worldwide. Its long-term focus remains on evolution and expansion within the global animal health market.
Farmabase has 2 tracked investments across 2 companies. The latest tracked deal is $6.2M Series A in Peptobiotics in April 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 10, 2024 | Peptobiotics | $6.2M Series A | Hatch Blue | Graincorp, Ponderosa Ventures, Seeds Capital, Seventure Partners, Claire Pribula, Trendlines Agrifood Fund |
| Apr 28, 2022 | Decoy Smart Control | $2.0M Seed | SP Ventures | — |